6-(4-Phenylpiperazino)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine | 334500-45-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-(4-Phenylpiperazino)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine
• 英文别名: 6-(4-phenylpiperazin-1-yl)-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazine
• CAS: 334500-45-7
• 化学式: C₁₆H₁₅F₃N₆
• 分子量: 348.331
• InChiKey: FPANLGWEGGGQOP-UHFFFAOYSA-N

物化性质

• 密度：
  1.47±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  6-氯-3-(三氟甲基)[1,2,4]噻唑并[4,3-b]吡嗪 、 N-苯基哌嗪 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 生成 6-(4-Phenylpiperazino)-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine
  参考文献：
  名称：

  Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer

  摘要：

  Chemical starting points were investigated for downregulation of the androgen receptor as an approach to treatment of advanced prostate cancer. Although prototypic steroidal downregulators such as 6a designed for intramuscular administration showed insufficient cellular potency, a medicinal chemistry program derived from a novel androgen receptor ligand 8a led to 6-[4-(4-cyanobenzyl)piperazin-1-yl]3-(trifluoromethyl)[1,2,4] triazolo[4,3-b] pyridazine (10b), for which high plasma levels following oral administration in a preclinical model compensate for moderate cellular potency. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.122

文献信息

• ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：Magenta Therapeutics Inc.

  公开号：US20210220408A1

  公开（公告）日：2021-07-22

  The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.
• Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer
  作者：Robert H. Bradbury、Neil J. Hales、Alfred A. Rabow、Graeme E. Walker、David G. Acton、David M. Andrews、Peter Ballard、Nigel A.N. Brooks、Nicola Colclough、Alan Girdwood、Urs J. Hancox、Owen Jones、David Jude、Sarah A. Loddick、Andrew A. Mortlock

  DOI：10.1016/j.bmcl.2011.06.122

  日期：2011.9

  Chemical starting points were investigated for downregulation of the androgen receptor as an approach to treatment of advanced prostate cancer. Although prototypic steroidal downregulators such as 6a designed for intramuscular administration showed insufficient cellular potency, a medicinal chemistry program derived from a novel androgen receptor ligand 8a led to 6-[4-(4-cyanobenzyl)piperazin-1-yl]3-(trifluoromethyl)[1,2,4] triazolo[4,3-b] pyridazine (10b), for which high plasma levels following oral administration in a preclinical model compensate for moderate cellular potency. (C) 2011 Elsevier Ltd. All rights reserved.